PT3506901T - Utilização de ácido quinurénico no tratamento da atrofia muscular - Google Patents

Utilização de ácido quinurénico no tratamento da atrofia muscular

Info

Publication number
PT3506901T
PT3506901T PT177807880T PT17780788T PT3506901T PT 3506901 T PT3506901 T PT 3506901T PT 177807880 T PT177807880 T PT 177807880T PT 17780788 T PT17780788 T PT 17780788T PT 3506901 T PT3506901 T PT 3506901T
Authority
PT
Portugal
Prior art keywords
muscle atrophy
treating muscle
tryptophan metabolites
metabolites
tryptophan
Prior art date
Application number
PT177807880T
Other languages
English (en)
Original Assignee
Metabrain Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabrain Res filed Critical Metabrain Res
Publication of PT3506901T publication Critical patent/PT3506901T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
PT177807880T 2016-09-05 2017-09-05 Utilização de ácido quinurénico no tratamento da atrofia muscular PT3506901T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1658239A FR3055548B1 (fr) 2016-09-05 2016-09-05 Utilisation de metabolites du tryptophane dans le traitement de l'atrophie musculaire

Publications (1)

Publication Number Publication Date
PT3506901T true PT3506901T (pt) 2021-06-22

Family

ID=58707596

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177807880T PT3506901T (pt) 2016-09-05 2017-09-05 Utilização de ácido quinurénico no tratamento da atrofia muscular

Country Status (13)

Country Link
US (1) US11369595B2 (pt)
EP (1) EP3506901B1 (pt)
JP (1) JP7175272B2 (pt)
KR (1) KR20190121285A (pt)
CN (1) CN109952102B (pt)
AU (1) AU2017318536C1 (pt)
CA (1) CA3034635A1 (pt)
DK (1) DK3506901T3 (pt)
ES (1) ES2878042T3 (pt)
FR (1) FR3055548B1 (pt)
PL (1) PL3506901T3 (pt)
PT (1) PT3506901T (pt)
WO (1) WO2018042141A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102699211B1 (ko) * 2018-03-19 2024-08-26 후지필름 가부시키가이샤 정신 질환의 판정 방법
CN111647640A (zh) * 2020-05-22 2020-09-11 中国药科大学 一种快速精准实现慢性心力衰竭心功能病程分级的方法
CN112168822B (zh) * 2020-09-27 2022-11-08 集美大学 犬尿酸在改善高脂饮食致血脂异常、肥胖、肠道菌群混乱中的用途
CN113350342A (zh) * 2021-06-01 2021-09-07 南京医科大学附属逸夫医院 犬尿喹啉酸在制备治疗骨质疏松相关疾病的药物中的用途
CN114438138A (zh) * 2022-02-24 2022-05-06 重庆市畜牧科学院 用生孢梭菌制备的代谢组合物及其生产方法、检测方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270309A (en) * 1987-08-12 1993-12-14 Merck Sharp & Dohme Limited Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders
AU2005302452B2 (en) 2004-11-01 2010-12-09 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in Amyotrophic Lateral Sclerosis
CA2594460A1 (en) 2005-01-14 2006-07-20 The Board Of Trustees Of The Leland Stanford Junior University A method of modulating t cell functioning
ITFI20050083A1 (it) * 2005-04-29 2006-10-30 Univ Firenze Uso dell'acido chinurenico per la prevenzione e il trattamento dello shock
HUP0700051A2 (en) 2007-01-17 2008-09-29 Univ Szegedi Use of kynurenic acid and derivatives there of for treating of gastrointestinal disorders associated with enhanced motility and inflammation
US8815936B2 (en) 2008-03-03 2014-08-26 Nad Life Pty Ltd Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders
WO2010007085A2 (en) * 2008-07-17 2010-01-21 Novartis Ag Use of organic compounds
UY32341A (es) 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
JP2012180331A (ja) 2011-03-03 2012-09-20 Meiji Co Ltd 筋損傷の早期回復の誘導用の経口摂取剤
AU2013271841B2 (en) 2012-06-05 2018-03-08 International Stem Cell Corporation Method of prevention of neurological diseases
RU2585372C1 (ru) 2012-08-17 2016-05-27 Китайский Медицинский Университет Фармацевтическая композиция для ингибирования аутофагии двигательных нейронов и её применение
WO2015085097A1 (en) * 2013-12-05 2015-06-11 The Broad Institute, Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
WO2016114655A1 (en) * 2015-01-12 2016-07-21 Ry Pharma B.V. Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation
FR3035105A1 (fr) * 2015-04-16 2016-10-21 Metabrain Res Derives utiles dans le traitement de l'atrophie musculaire

Also Published As

Publication number Publication date
ES2878042T3 (es) 2021-11-18
AU2017318536A1 (en) 2019-05-02
CA3034635A1 (fr) 2018-03-08
CN109952102A (zh) 2019-06-28
DK3506901T3 (da) 2021-06-21
EP3506901A1 (fr) 2019-07-10
FR3055548A1 (fr) 2018-03-09
PL3506901T3 (pl) 2021-11-02
FR3055548B1 (fr) 2018-09-28
EP3506901B1 (fr) 2021-03-24
RU2019109914A (ru) 2020-10-05
JP2019530743A (ja) 2019-10-24
AU2017318536B2 (en) 2023-08-10
KR20190121285A (ko) 2019-10-25
JP7175272B2 (ja) 2022-11-18
CN109952102B (zh) 2023-08-04
AU2017318536C1 (en) 2023-12-21
WO2018042141A1 (fr) 2018-03-08
US20190247385A1 (en) 2019-08-15
RU2019109914A3 (pt) 2020-12-14
US11369595B2 (en) 2022-06-28

Similar Documents

Publication Publication Date Title
HUS2100037I1 (hu) Vegyületek gerinc eredetû izomsorvadás kezelésére
ZA202006746B (en) Methods of treatment
EP3463355A4 (en) DUX4 MODULATORS FOR REGULATING MUSCLE FUNCTION
SI3518783T1 (sl) Naprava za zmanjševanje tkiva
PT3506901T (pt) Utilização de ácido quinurénico no tratamento da atrofia muscular
HUE058171T2 (hu) Eszköz a viszketés hipertermikus kezelésére
HK1246784A1 (zh) 用於治療脊髓性肌萎縮的化合物
IL268217A (en) exposure device
ZA201903649B (en) Treatment for primary biliary cholangitis
IL265342A (en) Use of pridofidine for the treatment of Rett syndrome
IL261277A (en) Combination therapies for treatment of spinal muscular atrophy
ZA201906047B (en) Compounds for treating tuberculosis
RS63345B1 (sr) Seladelpar za lečenje primarnog bilijarnog holangitisa
PT3283064T (pt) Derivados úteis para o tratamento da atrofia muscular
PL3700486T3 (pl) Aparat do obracania pacjenta
GB201809050D0 (en) Modulators of tryptophan catabolism
PL3308752T3 (pl) Urządzenie do hipertermicznego leczenia świądu
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
EP3448869A4 (en) AZASTEROIDS FOR TUBERCULOSIS TREATMENT
TR201604127A2 (en) Use of composition that contains local anesthetic for treating nausea
ZA201805215B (en) Preparation for nasal-nasopharyngeal treatment
GB201810835D0 (en) Methods of use
HU4807U (hu) Berendezés kolloidok elektrokoagulációs kezelésére